| Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | ||
|---|---|---|---|---|---|---|
Revenues: | ||||||
Grant revenue | ||||||
13,405 | 3,966 | - | - | - | ||
Collaboration revenue | ||||||
4,742 | - | - | - | - | ||
Total revenues | ||||||
18,147 | 3,966 | 1,979 | 335 | - | ||
Operating expenses: | ||||||
Research and development | ||||||
65,775 | 33,885 | 32,869 | 26,333 | 11,125 | ||
General and administrative | ||||||
15,588 | 12,887 | 10,840 | 7,223 | 2,202 | ||
Total operating expenses | ||||||
81,363 | 46,772 | 43,709 | 33,556 | 13,327 | ||
Loss from operations | ||||||
-63,216 | -42,806 | -41,730 | -33,221 | -13,327 | ||
Other income (expense): | ||||||
Gain on settlement of derivative liability | ||||||
223 | - | - | - | - | ||
Interest income | ||||||
1,328 | 1,101 | - | - | - | ||
Change in fair value of derivative liabilities | ||||||
- | - | 1,541 | 580 | -174 | ||
Interest income and other income (expense), net | ||||||
- | - | 303 | - | - | ||
Other income (expense), net | ||||||
740 | 43 | 1,844 | 580 | 174 | ||
Total other income (expense), net | ||||||
2,291 | 1,144 | - | - | - | ||
Net loss | ||||||
-60,925 | -41,662 | -39,886 | -32,641 | -13,153 | ||
Less: Net loss attributable to non-controlling interest | ||||||
- | - | -1,143 | -7,150 | -2,999 | ||
Net loss attributable to Spero Therapeutics, Inc. | ||||||
- | - | -38,743 | -25,491 | -10,154 | ||
Cumulative dividends on redeemable convertible preferred shares | ||||||
- | - | 6,146 | 3,441 | 932 | ||
Accretion of redeemable bridge units and redeemable convertible preferred shares to redemption value | ||||||
- | - | 1,208 | 996 | 2,341 | ||
Net loss attributable to common shareholders of Spero Therapeutics, Inc. | ||||||
- | - | -46,097 | -29,928 | -13,427 | ||
Net loss per share attributable to common stockholders, basic and diluted | ||||||
-3.35 | -2.60 | -17.82 | -95.87 | -53.11 | ||
Weighted average common shares outstanding, basic and diluted: | ||||||
18,160 | 16,001 | 2,586 | 312 | 252 | ||
Comprehensive loss: | ||||||
Net loss | ||||||
-60,925 | -41,662 | -39,886 | -32,641 | -13,153 | ||
Other comprehensive gain (loss): | ||||||
Unrealized gain (loss) on marketable securities | ||||||
38 | -28 | - | - | - | ||
Reclassification adjustment for gains included in net loss | ||||||
-6 | - | - | - | - | ||
Net unrealized gains (losses) on securities | ||||||
44 | -28 | - | - | - | ||
Total comprehensive loss | ||||||
-60,881 | -41,690 | -39,886 | -32,641 | - | ||